184 related articles for article (PubMed ID: 27821435)
1. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
2. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
3. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.
Yu J; Ritchie TK; Mulgaonkar A; Ragueneau-Majlessi I
Drug Metab Dispos; 2014 Dec; 42(12):1991-2001. PubMed ID: 25271211
[TBL] [Abstract][Full Text] [Related]
4. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
Yu J; Wang Y; Ragueneau-Majlessi I
Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
[TBL] [Abstract][Full Text] [Related]
7. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
Venkatakrishnan K; Pickard MD; von Moltke LL
Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
[TBL] [Abstract][Full Text] [Related]
8. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
[TBL] [Abstract][Full Text] [Related]
9. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions.
Ahmed MA; Kalaria SN; Younis IR
J Clin Pharmacol; 2021 Oct; 61(10):1324-1333. PubMed ID: 33997992
[TBL] [Abstract][Full Text] [Related]
11. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.
Yu J; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jul; 13(4):693-699. PubMed ID: 31981398
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
14. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
15. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade.
Younis IR; Manchandani P; Hassan HE; Qosa H
Clin Pharmacol Ther; 2022 Sep; 112(3):635-642. PubMed ID: 35780478
[TBL] [Abstract][Full Text] [Related]
16. Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels.
Conrado DJ; Rogers HL; Zineh I; Pacanowski MA
Pharmacogenomics; 2013 Jan; 14(2):215-23. PubMed ID: 23327581
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.
Zhang Y; Zhang L; Abraham S; Apparaju S; Wu TC; Strong JM; Xiao S; Atkinson AJ; Thummel KE; Leeder JS; Lee C; Burckart GJ; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2009 Mar; 85(3):305-11. PubMed ID: 19020495
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
20. Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation.
Hsueh CH; Hsu V; Pan Y; Zhao P
Clin Pharmacokinet; 2018 Oct; 57(10):1337-1346. PubMed ID: 29455429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
